New drug approved for treating chronic schizophrenia with fewer side effects. Could be beneficial for Black community.

Among the 55 novel drugs that crossed the regulatory finish line last year were notable new mechanisms of action, coming ...

Researchers reveal that daily use of high-potency cannabis significantly increases the risk of developing psychosis, ...

Bristol Myers Squibb’s Cobenfy achieved an 8.4-point PANSS improvement over placebo after five weeks in a phase 3 trial that ...

Abbvie said on Friday it would record a charge of about $3.5 billion related to its experimental schizophrenia drug, ...

Quetiapine is an antipsychotic medication that people who live with schizophrenia or bipolar rely on. Pharmacists say they ...

In those with first episode psychosis, a long duration of untreated psychosis was linked to negative psychotic symptoms and lower symptom remission.

Intra-Cellular Therapies’ performance in the stock market has been impressive, especially considering the broader market environment. The company’s stock is up +52.51% year-to-date (YTD), a remarkable ...

An antipsychotic medication often prescribed to people with schizophrenia or bipolar is ... stop taking it suddenly due to the risk of side effects or relapses. Abruptly stopping the drug can ...

Treatment-resistant schizophrenia (TRS) is generally understood as a failure to respond to at least two trials of ...